J. Golec

发表

Option Trading, Managerial Risk-taking, and New Brands*

Fan Yang, I. Hasan, Wei-Ming Lee, 2020 .

Economic Evaluation and Cost-Effectiveness Thresholds

John A. Vernon, Robert Goldberg, J. Vernon, 2012, PharmacoEconomics.

Economic Evaluation and Comparative-Effectiveness Thresholds: Signals to Firms and Implications for R&D Investment and Innovation

J. Vernon, J. Golec, John A. Vernon, 2009 .

New estimates of the cost of capital for pharmaceutical firms

John A. Vernon, Joseph H. Golec, Carmelo Giaccotto, 2011 .

Debt Capacity of Real Estate Collateral

Armin Schwienbacher, J. Golec, Erasmo Giambona, 2014 .

Strategic Trading in the Wrong Direction By a Large Institutional Insider

J. Golec, Erasmo Giambona, 2009 .

A Comparison of Hospital Utilization by Medicaid and Privately Insured Patients

M. Arndt, J. Golec, R. C. Bradbury, 1998, Medical care research and review : MCRR.

Do Investors See through Mistakes in Reported Earnings?

John P. Harding, J. Golec, K. Bardos, 2010, Journal of Financial and Quantitative Analysis.

Relating hospital health outcomes and resource expenditures.

J. Golec, R. C. Bradbury, P. Steen, 1994, Inquiry : a journal of medical care organization, provision and financing.

Occurrence of Validating Clinical Findings in the Hospital Record for Appendectomy, Cholecystectomy and Intervertebral Disc Excision Patients: Comparisons among Hospitals and among Surgeons

J. Golec, R. C. Bradbury, P. Steen, 1996, Health services management research.

Comparing Surgical Efficiency in Independent Practice Association HMOS and Traditional Insurance Programs

J. Golec, R. C. Bradbury, F. E. Stearns, 1993, Health services management research.

Toward a Systems Quality Paradigm: Relating Health Outcomes, Resource Expenditures, and Appropriateness of Cholecystectomy Patients

J. Golec, R. C. Bradbury, P. Steen, 1997, Health services management research.

Comparing hospital length of stay in independent practice association HMOs and traditional insurance programs.

J. Golec, R. C. Bradbury, F. E. Stearns, 1991, Inquiry : a journal of medical care organization, provision and financing.

Financial Risk in the Biotechnology Industry

J. Vernon, J. Golec, 2007 .

Do bettors prefer long shots because they are risk-lovers, or are they just overconfident?

M. Tamarkin, J. Golec, 1995 .

Regulation And The Rise In Asset‐Based Mutual Fund Management Fees

J. Golec, 2003 .

Are the Insider Trades of a Large Institutional Investor Informed?

J. Golec, 2007 .

Comparing Uninsured and Privately Insured Hospital Patients: Admission Severity, Health Outcomes and Resource use

J. Golec, R. C. Bradbury, P. Steen, 2001 .

Comparing uninsured and privately insured hospital patients: admission severity, health outcomes and resource use

J. Golec, R. C. Bradbury, P. Steen, 2001, Health services management research.

Do the Large Trades of an Institutional Investor Reflect Private Information ?

J. Clapp, J. Golec, 2003 .

Compensation policies and financial characteristics of real estate investment trusts

J. Golec, 1994 .

Measuring the patient health, societal and economic benefits of US pediatric therapeutics legislation.

A. Allen, J. Vernon, J. Golec, 2012, Paediatric drugs.

Pharmaceutical Price Regulation: Public Perceptions, Economic Realities, and Empirical Evidence

J. Vernon, J. Golec, 2009 .

Future of drug development: the economics of pharmacogenomics

J. Vernon, J. Golec, K. Hughen, 2005, Expert review of clinical pharmacology.

The effects of mutual fund managers' characteristics on their portfolio performance, risk and fees

Joseph H. Golec, J. Golec, 1996 .

Exploration of Potential Economics of Follow-On Biologics and Implications for Data Exclusivity Periods for Biologics

John A. Vernon, Joseph H. Golec, A. Bennett, 2009 .

LITIGATION RISK AND MARKET REACTION TO RESTATEMENTS: Litigation Risk

John P. Harding, J. Golec, K. Bardos, 2013 .

Indications for Hysterectomy: Variation within and Across Hospitals

M. Arndt, J. Golec, R. C. Bradbury, 1995, Medical care research and review : MCRR.

The degree of inefficiency in the football betting market: Statistical tests

Maurry Tamarkin, M. Tamarkin, J. Golec, 1991 .

The degree of inefficiencyin the football betting market

M. Tamarkin, J. Golec, 1991 .

Linking Health Outcomes and Resource Efficiency for Hospitalized Patients: Do Physicians with Low Mortality and Morbidity Rates Also Have Low Resource Expenditures?

J. Golec, R. C. Bradbury, P. Steen, 2000, Health services management research.

Do Firms Purposefully Change Capital Structure? Evidence from an Investment-Opportunity Shock to Drug Firms

Florencio López‐de‐Silanes, J. Golec, Erasmo Giambona, 2020, Journal of Financial and Quantitative Analysis.

Financial risk of the Biotech Industry versus the Pharmaceutical Industry

J. Vernon, J. Golec, 2009 .

Pharmaceutical R&D Spending and Threats of Price Regulation

J. Vernon, J. Golec, S. Hegde, 2008, Journal of Financial and Quantitative Analysis.

Estimating risk‐return relationships: An analysis of measures

David A. Baucus, J. Golec, J. R. Cooper, 1993 .

Pharmaceutical Stock Price Reactions to Price Constraint Threats and Firm-Level R&D Spending

J. Vernon, J. Golec, S. Hegde, 2005 .

Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms

J. Vernon, J. Golec, 2012, PharmacoEconomics.

The Economics of Pharmaceutical Price Regulation and Importation: Refocusing the Debate

J. Vernon, J. Golec, W. Hughen, 2006, American Journal of Law & Medicine.

Performance fee contract change and mutual fund risk

L. Starks, J. Golec, 2004 .

The Financial Effects of Fuel Adjustment Clauses on Electric Utilities

J. Golec, 1990 .

The Growth Opportunity Channel of Debt Structure

J. Golec, Erasmo Giambona, 2013 .

Bettors Love Skewness, Not Risk, at the Horse Track

Joseph H. Golec, Maurry Tamarkin, M. Tamarkin, 1998, Journal of Political Economy.

New estimates of pharmaceutical research and development spending by US-based firms from 1984 to 2003

J. Vernon, J. Golec, 2007 .

Real Option Value and Path Dependence in Oncology Innovation

G. Pink, J. Vernon, J. Golec, 2011 .

Using Options to Measure the Full Value-Effect of an Event: Application to Obamacare

J. Golec, Paul Borochin, 2013 .

Surgeon volume and hospital resource utilization.

M. Arndt, J. Golec, R. C. Bradbury, 1995, Inquiry : a journal of medical care organization, provision and financing.

Measuring the Performance of the Secondary Market for Life Insurance Policies

Carmelo Giaccotto, J. Golec, Bryan P Schmutz, 2017 .

Drug development costs when financial risk is measured using the Fama-French three-factor model.

J. DiMasi, J. Vernon, J. Golec, 2009, Health economics.

Does Earnings Management Relieve the Negative Effects of Mandatory Pension Contributions?: Mandatory Pension Contributions and Earnings Management

Hieu V. Phan, Hinh D. Khieu, J. Golec, 2017 .

Does Earnings Management Relieve the Negative Effects of Mandatory Pension Contributions?

Hieu V. Phan, Hinh D. Khieu, J. Golec, 2015 .

Herding on Noise: The Case of Johnson Redbook's Weekly Retail Sales Data

J. Golec, 1997, Journal of Financial and Quantitative Analysis.

Empirical Tests of a Principal-Agent Model of the Investor-Investment Advisor Relationship

Joseph H. Golec, J. Golec, 1992, Journal of Financial and Quantitative Analysis.

Comparative Effectiveness Research (CER) Policies and the Potential Threat to Pharmaceutical Innovation

John A. Vernon, Joseph H. Golec, Stedman Stevens, 2010 .

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending

J. Vernon, J. Golec, 2006 .

Comparative Effectiveness Regulations and Pharmaceutical Innovation

J. Vernon, J. Golec, J. Stevens, 2012, PharmacoEconomics.

Do Firms Purposefully Change Capital Structure?: Evidence from a Growth Shock to Pharmaceutical Firms

J. Golec, Erasmo Giambona, Florencio López de Silanes, 2018 .

Debt Structure and Growth Prospects: Evidence from the Introduction of Biosimilar Drugs

J. Golec, Erasmo Giambona, Florencio López de Silanes, 2016 .

Informed Options Trading Before Fda Drug Advisory Committee Meetings

J. Golec, Paul Borochin, Zekun Wu, 2021 .

Mutual fund volatility timing and management fees

Joseph H. Golec, Erasmo Giambona, J. Golec, 2009 .

Incentive Fees and Mutual Fund Volatility Timing

J. Golec, Erasmo Giambona, 2007 .

Measuring the Patient Health, Societal and Economic Benefits of US Pediatric Therapeutics Legislation

A. Allen, J. Vernon, J. Golec, 2012, Pediatric Drugs.

An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending

R. Lutter, J. Vernon, J. Golec, 2009 .

Litigation Risk and Market Reaction to Restatements

John P. Harding, J. Golec, K. Bardos, 2009 .

The Conditional Performance of REIT Stock Repurchases

Carmelo Giaccotto, J. Golec, Erasmo Giambona, 2006 .

Conflicts of Interest on Committees of Experts: The Case of Food and Drug Administration Drug Advisory Committees

James C. Cooper, J. Golec, 2019, The Journal of Law and Economics.

Conflicts of Interest on Expert Committees: The Case of FDA Drug Advisory Committees

James C. Cooper, J. Golec, 2017 .

Do investments in intangible customer assets affect firm value

J. Golec, Neeraj J. Gupta, 2014 .

Do Investors Use Customer Metrics to Value High Growth Service Firms?

J. Golec, Neeraj J. Gupta, 2012 .

The Case for Less, Not More, US FDA Regulation

J. Vernon, J. Golec, 2011, PharmacoEconomics.

Measuring US Pharmaceutical Industry R&D Spending

J. Vernon, J. Golec, 2012, PharmacoEconomics.

How excluding some benefits from value assessment of new drugs impacts innovation*

J. Golec, Joseph P. Cook, 2016, Health economics.

Fewer Drugs, Shorter Lives, Less Prosperity: The Impact of Comparative Effectiveness Research on Health and Wealth

Peter J. Pitts, J. Vernon, J. Golec, 2011 .

Correctly measuring drug development risk: a public policy imperative

J. Vernon, J. Golec, 2011, Expert review of pharmacoeconomics & outcomes research.

Drug development costs when financial risk is measured using the Fama-French three-factor model.

J. DiMasi, J. Vernon, J. Golec, 2009, Health economics.

Future of drug development: the economics of pharmacogenomics

J. Vernon, J. Golec, K. Hughen, 2008, Expert review of clinical pharmacology.

Fda New Drug Approval Times, Prescription Drug User Fees, and R&D Spending

R. Lutter, J. Vernon, J. Golec, 2006 .